Entropy Technologies LP Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

Entropy Technologies LP acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 18,440 shares of the medical research company’s stock, valued at approximately $3,624,000.

A number of other large investors have also recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in IQVIA in the 3rd quarter valued at approximately $147,683,000. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Finally, KBC Group NV raised its holdings in IQVIA by 68.5% in the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after buying an additional 250,458 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research reports. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday. Barclays decreased their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Price Performance

Shares of NYSE:IQV opened at $208.13 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The stock’s fifty day simple moving average is $200.67 and its two-hundred day simple moving average is $219.54. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a market cap of $37.78 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.